AU4374297A - Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors - Google Patents

Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors

Info

Publication number
AU4374297A
AU4374297A AU43742/97A AU4374297A AU4374297A AU 4374297 A AU4374297 A AU 4374297A AU 43742/97 A AU43742/97 A AU 43742/97A AU 4374297 A AU4374297 A AU 4374297A AU 4374297 A AU4374297 A AU 4374297A
Authority
AU
Australia
Prior art keywords
abilities
protein
affect
activity
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43742/97A
Inventor
Michael Dennis
Jean Labrecque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU4374297A publication Critical patent/AU4374297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU43742/97A 1996-10-02 1997-10-02 Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors Abandoned AU4374297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2186979 1996-10-02
CA 2186979 CA2186979A1 (en) 1996-10-02 1996-10-02 Methods of testing antagonists for their abilities to affect the activity of g protein-coulpled receptors
PCT/CA1997/000713 WO1998014780A1 (en) 1996-10-02 1997-10-02 Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors

Publications (1)

Publication Number Publication Date
AU4374297A true AU4374297A (en) 1998-04-24

Family

ID=4159007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43742/97A Abandoned AU4374297A (en) 1996-10-02 1997-10-02 Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors

Country Status (3)

Country Link
AU (1) AU4374297A (en)
CA (1) CA2186979A1 (en)
WO (1) WO1998014780A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) * 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
GB0217551D0 (en) * 2002-07-30 2002-09-11 Amersham Biosciences Uk Ltd Perturbation effect recognition
FR3012479B1 (en) * 2013-10-31 2016-01-01 Soletanche Freyssinet CABLES VIBRATION DAMPING DEVICE OF AN ART WORK SUSPENSION SYSTEM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138621A1 (en) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int METHOD FOR SCREENING SUBSTANCES WITH MODULATING EFFECT ON A RECEPTACLE-RELATED CELLULAR SIGNAL TRANSMISSION PATH
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5677184A (en) * 1994-04-19 1997-10-14 Takeda Chemical Industries, Ltd. CHO cells that express human LH-RH receptor
CA2135253A1 (en) * 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
JPH11507518A (en) * 1995-06-07 1999-07-06 プレーシス ファーマスーティカルズ インコーポレイテッド Functional bioassay for agonists and antagonists of receptors coupled to G proteins
WO1997019352A1 (en) * 1995-11-22 1997-05-29 Novartis Ag Therapeutic agents and screening method

Also Published As

Publication number Publication date
WO1998014780A1 (en) 1998-04-09
CA2186979A1 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
PL329725A1 (en) Indole derivatives useful as antagonists of endotelin receptor
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
AU5440996A (en) 2-acylaminopropanamides as tachykinin receptor antagonists
IL130761A0 (en) Intermediates for the preparation of estrogen agonists/antagonists
PL337809A1 (en) Derivatives of 1-aminoalkyl cyclohexane as antagonists of nmda receptor
AU2616495A (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
PT832082E (en) N-HETEROARIL-PYRIDINESULFONAMID DERIVATIVES AND THEIR USE AS ENDOTHELINE ANTAGONISTS
AU4718093A (en) Substituted amines as tachykinin receptor antagonists
ZA964744B (en) Crf receptor antagonists and methods relating thereto
ZA9610736B (en) 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
PL335100A1 (en) Oxazolynones as antagonists of 5ht2a receptor
IL127304A0 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
EP1111049A4 (en) Novel receptor protein and method for diagnosing inflammatory diseases by using the same
PL338453A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
AU4374297A (en) Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors
IL127417A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
AU4930696A (en) Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
AU5627194A (en) New use of 5-ht3 receptor antagonists
AU3249997A (en) Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization
PL338456A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
AU7460194A (en) 2-phenylpyrrole derivatives as dopamine d3 receptor antagonists
AU4559297A (en) Quinuclidine derivatives as antagonists of muscarinic receptors
AU2773595A (en) Structural models for cytoplasmic domains of transmembrane receptors
HUP0102531A3 (en) Carboxy substituted carboxamide derivatives and their use as tachykinin receptor antagonists
AU5168800A (en) Structural models for cytoplasmic domains of transmembrane receptors